Neurology. 1994 Nov;44(11 Suppl 9):S70-8.
Tizanidine was evaluated in a prospective, double-blind, randomized, placebo-controlled trial in 187 patients with MS. Taken orally for 9 weeks and preceded by a titration phase for a period of 3 weeks starting at 2 mg daily, tizanidine produced a significant reduction in spastic muscle tone compared with placebo treatment. Within the effective dose range of 24 to 36 mg given daily in three doses, tizanidine achieved a 20% mean reduction in muscle tone. Approximately 75% of patients, with all degrees of spasticity, reported subjective improvement without an increase in muscle weakness, but there was no improvement in activities of daily living depending on movement. Tizanidine achieved its maximum effect on spasticity within 1 week of the start of treatment; the benefit was maintained for at least 1 week after discontinuation of therapy. A variety of adverse events was recorded by patients taking tizanidine, but these were minor and reversible, and rarely limited treatment. Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity.
在一项针对187例多发性硬化症患者的前瞻性、双盲、随机、安慰剂对照试验中对替扎尼定进行了评估。替扎尼定口服9周，在开始每天2毫克的3周滴定期之后，与安慰剂治疗相比，其能显著降低痉挛性肌张力。在每天分三次服用24至36毫克的有效剂量范围内，替扎尼定使肌张力平均降低了20%。大约75%的不同程度痉挛患者报告主观症状改善，且肌肉无力未加重，但依赖运动的日常生活活动并无改善。替扎尼定在治疗开始后1周内对痉挛达到最大效果；停药后疗效至少维持1周。服用替扎尼定的患者记录了多种不良事件，但这些都是轻微且可逆的，很少限制治疗。替扎尼定是一种耐受性良好且有效的治疗痉挛症状的药物。
